Clinical Trial Update: DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] [Phase 3]

View source ↗

Summary

Phase 3 DESTINY-Breast02 trial of Enhertu (trastuzumab deruxtecan, DS-8201a) in pre-treated unresectable or metastatic HER2-positive breast cancer has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2023-06-26